To study analyze maternal serum alpha-fetoprotein as a biomarker of placental adherence in low lying placenta

Pooja Verma; Kavita N. Singh; Vineeta Ghanghoriya

doi:10.18203/2320-1770.ijrcog20161698

Authors

Pooja Verma Department of Obstetrics and Gynecology, Netaji Subhash Chandra Bose Medical College and Hospital, Jabalpur, Madhya Pradesh, India
Kavita N. Singh Department of Obstetrics and Gynecology, Netaji Subhash Chandra Bose Medical College and Hospital, Jabalpur, Madhya Pradesh, India
Vineeta Ghanghoriya Department of Obstetrics and Gynecology, Netaji Subhash Chandra Bose Medical College and Hospital, Jabalpur, Madhya Pradesh, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20161698

Keywords:

Low lying placenta, Placental adherence, MSAFP

Abstract

Background: To study the place of Maternal Serum Alfa Feto Protein (MSAFP) as a biomarker of placental adherence in low lying placenta, and to study maternal outcome in the study group.

Methods: This is a prospective observational study analyzing the conditions and the data of 90 cases with low lying placenta in a tertiary care hospital. The analysis was done for the association of MSAFP with MRI, perinatal and maternal outcome.

Results: The level of MSAFP was found higher in 14 out of 15 cases (93.3%) of placenta previa with placental adherence. There was significant surgical intervention (80%) and increased maternal morbidity (68.8%) in the study group with placental adherence and raised MSAFP respectively.

Conclusions: MSAFP is an important biomarker for prognostication of placental adherence in low lying placenta.

Metrics

Metrics Loading ...

References

Martin JA, Hamilton B E, Sutton PD et al. Birth final data for 2003. National vital statistics report. 2005;54(2).

Cunningham FG, MacDonald PC, Gant NF, Leveno KJ, Gilstrap LC, Hankins GDV, et al. Obstetrical hemorrhage. In: Williams Obstetrics, 20th ed. Appleton & Lange: Stamford. 1997:755-6.

Silver, Robert M, Landon Mark B. Maternal morbidity associated with multiple repeat cesarean delivery. Obstet Gynecol. 2006;107(6):1226-32.

Al-Serehi A, Mhoyan A, Brown M, Benirschke K, Hull A, Pretorius DH. Placenta accreta: an association with fibroids and Asherman syndrome. J Ultrasound Med. 2008;27:1623-8.

Hamar BD, Wolff EF, Kodaman PH, Marcovici I. Premature rupture of membranes, placenta increta, and hysterectomy in a pregnancy following endometrial ablation. J Perinatol. 2006;26:135-7.

Pron G, Mocarski E, Bennett J, Vilos G, Common A, Vanderburgh L. Pregnancy after uterine artery embolization for leiomyomata: the Ontario multicenter trial. Ontario UFE Collaborative Group. Obstet Gynecol. 2005;105:67-76.

Berkeley AS, Killackey MA, Cedarqvist LL. Elevated maternal serum alpha-fetoprotein levels associated with breakdown in fetal–maternal–placental barrier. Am J Obstet Gynecol. 1983;146:85.

Morssink LP, de Wolf BT, Kornman LH. The relation between serum markers in the second trimester and placental pathology: a study on extremely small for gestational age fetuses. BJOG. 1996;103:779-83.

Chandra S, Scott H, Dodds L, et al. elevated maternal serum α-fetoprotein and/or human chorionic gonadotropin and the risk of adverse outcomes. Am J Obstet Gynecol. 2003;189:775-81.

Zelop C, Nadel A, Frigoletto FD Jr. Placenta accreta/precreta/ increta: a cause of elevated maternal serum alpha-fetoprotein. Obstet Gynecol. 1992;80:693-4.

Kupferminc MJ, Tamura RK, Wigton TR. Placenta accreta is associated with elevated maternal serum alpha-fetoprotein. Obstet Gynecol. 1993;82:266-9.

Williams. Textbook of Obstetrics. F. Gary Cunningham. Chpt. 35 - Obstetrical Hemorrhage. 23rd edition United States of America. McGraw-Hill; 2010:769

Cleary-Goldman J. Impact of maternal age on obstetric outcome. Obstet Gynecol. 2005;105:983.

Babinszki A, Kerenyi T. Perinatal outcome in grand and great grand multiparity. Effects of parity on obstetric risk factors.Am J Obstet Gynecol. 1999;181:669.

Ananth CV, Demissie K, Smulian JC. Placentanprevia in singleton and twin births in the United States, 1989 through 1998. A comparison of risk factor profiles and associated conditions. Am J Obstet Gynecol. 2003a;188:275.

Lala ABH, Rutherford JM. Massive or recurrent ante partum haemorrhage. Current Obstetrics and Gynaecology. 2002;12:226-30.

Goetzinger KR, Odibo AO. Screening for abnormal placentation and adverse pregnancy outcomes with maternal serum biomarkers in the second trimester. John Wiley and sons ltd. 2014;10(1002):4370.

Mcduffie RS Harkness L, Mcvay RM. Mid trimester hemoperitoneum caused by placenta percreta in association with elevated MSAFP. American journal of obstetrics $ gynecology.1994;171(2):565-6.

Hung T, Shau W, Hsieh C, Chiu T. Risk factors for placenta accreta. Obstet Gynecol. 1999;93:545–50.

Oyelese Y, Smulian JC. Placenta Previa. Obstet Gynecol. 2006;10(4):927.

Gagnon A, Wilson RD, Audibert F. Obstetrical complications associated with abnormal maternal serum markers analytes. Journal of Obstetrics and Gynecology Canada. 2008;30(10):918-49.

Butler EL, Ronald MM. Association between Maternal Serum Alpha‐Fetoprotein and Adverse Outcomes in Pregnancies With Placenta Previa. Obstetrics and Gynecology. 2001;97(1):35-8.

Silver RM, Barbour KD. Plaenta Accreta Spectrum. Clinical Review articles. Obst and Gynecol. Clinics of North America. 2015;42(2):381-402.